Additionally, the system enabled the topical delivery of siRNA targeting transforming growth factor beta receptor 1 (TGFβR-1), which is overexpressed in about 80% of patients with squamous cell carcinoma (SCC) of the skin, its suppression presenting anti-tumor effects. The gene discussed is TGFBR1; the disease is squamous cell carcinoma.